Related Experiment Video
Updated: Jul 22, 2026
Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
Published on: November 9, 2016
Novel Use of Botulinum Toxin in Long-Standing Adductor-Related Groin Pain: A Case Series
Alexandre Creuzé1,2, Thomas Fok-Cheong1,3, Adam Weir4,5,6
1Centre Hospitalier Universitaire de Bordeaux, Service de Médecine Physique et de Réadaptation, Unité de Médecine Orthopédique et Sportive, Bordeaux, Aquitaine, France.
Background:
Adductor-related groin pain (ARGP) is the most common groin injury in athletes. If conservative treatment fails, then adductor tenotomy to relieve tension can be considered. The use of botulinum toxin A (BoNT-A) has shown good results in other musculoskeletal pathologies.
Objective:
Assess the effectiveness of BoNT-A injections in ARGP in cases where usual treatment has failed.
Design:
Retrospective cohort study.
Setting:
Orthopedic Medicine and Rehabilitation Unit, University of Bordeaux.
Participants:
Fifty patients treated by BoNT-A injection in ARGP after failure of medical and/or surgical treatment were included in this study.
Interventions:
One or several adductor muscles were injected with BoNT-A, according to clinical evaluation using ultrasound and electrical stimulation guidance. Patients were followed up at 1, 3, 6, and 12 months.
Main Outcome Measures:
The primary assessment criterion was the improvement of Hip and Groin Outcome Score subscales at day 30. Secondary outcomes included pain intensity and impact on sport, work, and quality of life (QoL), the Blazina scale, and side effects.
Results:
All the first 50 injected patients (45 male and 5 female patients) were included. A significant improvement was noted regarding the majority of Hip and Groin Outcome Score subscales at day 30 ( P < 0.05). Pain intensity and its impacts were both significantly reduced ( P < 0.001): less sport and professional disability and lower impact on QoL. Severity of symptoms assessed by the Blazina scale was significantly reduced ( P < 0.001). The improvements remained significant until 1-year postinjection.
Conclusions:
BoNT-A is promising as a new treatment for ARGP but should be fully assessed in a randomized controlled trial.
